1Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.
Opna Bio, South San Francisco, California.
1Integrative Anthropological Sciences, University of California, Santa Barbara, Santa Barbara, California. *Corresponding Author: Amy M. Boddy, Integrative ...
1Inocras Inc., San Diego, California. 2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. *Corresponding Author: Young ...
Washington University In St. Louis, St. Louis, MO.
Abstract. Molecular glue degrader (MGD) is an emerging therapeutic strategy offering an exciting alternative to traditional small molecules exploring new target space. These small molecules interact ...
The combination of anti-TROP2 ADCs with PD-(L)1 inhibitors represents a promising therapeutic strategy, merging targeted therapy with immunotherapy to improve treatment outcomes. Clinical trials are ...
Search for other works by this author on: ...
Search for other works by this author on: ...
University of Minnesota, Minneapolis, MN.
The University of Texas MD Anderson Cancer Center, Houston, TX.
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio (avelumab), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results